Medis

We are a fully integrated commercialization company focused on bringing life-changing therapies to patients in Central and Eastern Europe and Greece. As we proudly celebrate our 35th anniversary, we demonstrate a strong reputation in the region and established partnerships with some of the world’s leading pharmaceutical and biotech companies. Despite the region's challenging healthcare systems and complex markets, our team of 400 employees leverages its expertise and strong relationships with local healthcare professionals to ensure health equity in this often-overlooked region by global pharmaceutical companies. Medis is a member of the World Orphan Drug Alliance (WODA) – a global alliance of full-service regional distributors for rare and specialty portfolios. WODA covers 158 countries, offering unique commercial platform for the most extensive global coverage. Our business areas: • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners: Integrated commercialization model across regulatory, access, medical, sales and marketing • Proven track record with 150+ reimbursement successes • One point of accountability for 18 markets • Expertise in navigating complex healthcare and reimbursement systems • Strong KOL relationships for faster patient access • Uncompromising ethics, quality and compliance • Financial strength and long-term stability Major Partners: • Therapeutics: Bial – Biogen – Besins – Esteve – HRA Pharma – Italfarmaco –Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Enovis – Gaumard – Loccioni – Optiplan – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics – Crown Aesthetics • Out-licensing partners: Ferrer – Menarini – Pharmalink – Sarantis – Stada